Jaguar Health announces results of survey of U.S. veterinary oncologists

Jaguar Health announced the results of a survey of 26 U.S. veterinary oncologists regarding Canalevia-CA1, the company’s U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs. The study was conducted by Jaguar at the Veterinary Cancer Society Collaborative Conference, which took place April 19-22, 2023 in Cancun, Mexico. Highlights of the survey of veterinary oncologists include: Of the 12 participants who responded to the question "Do you tend to use Canalevia-CA1 first line for CID?", four indicated that they use the product first line. Twelve participants responded to the question "How would you rate Canalevia-CA1 in the following areas?", which had five subcategories: Efficacy, Onset of Action, Safety, Ease of Administration, and Cost, all ranked on a scale of 1 to 7. On average, the respondents ranked Efficacy 5.67, Onset of Action 5.58, Safety 6.75, Ease of Administration 6.08, and Cost 3.42. Twelve participants responded to the question "How would you compare Canalevia-CA1 to the SOC?", which had five subcategories: Canalevia-CA1 is superior in efficacy to the SOC, Canalevia-CA1 is superior in onset of action to the SOC, Canalevia-CA1 is superior in safety to the SOC, Canalevia-CA1 is superior in ease of administration to the SOC, and Canalevia-CA1 is superior in terms of cost to the SOC, all ranked on a scale of 1 to 7. The averages of responses were as follows: Canalevia-CA1 is superior in efficacy to the SOC: 5.25; Canalevia-CA1 is superior in onset of action to the SOC: 4.92; Canalevia-CA1 is superior in safety to the SOC: 5.25; Canalevia-CA1 is superior in ease of administration to the SOC: 4.67; Canalevia-CA1 is superior in terms of cost to the SOC: 1.67. No head-to-head clinical studies comparing Canalevia-CA1 to the current SOC therapy for CID in dogs have taken place.